Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HNF4A | P41235 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1416240 | 0.85 | ALDH1A1 (0.59) | ALDH1A1CYP1A2CYP2D6CYP2C19GRIN2D | |
| SCHEMBL10631372 | 0.84 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2D6CYP2C19GRIN2D | |
| SCHEMBL26626577 | 0.84 | GRIN2D (0.44) | ALDH1A1CYP1A2CYP2D6CYP2C19GRIN2D | |
| SCHEMBL10628873 | 0.84 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2D6CYP2C19GRIN2D | |
| Hydrochloric Acid SCHEMBL9898760 | 0.84 | ALDH1A1 (0.57) | ALDH1A1CYP1A2CYP2D6CYP2C19GRIN2D | |
| SCHEMBL450116 | 0.84 | COMT (0.44) | ALDH1A1CYP1A2CYP2D6CYP2C19GRIN2D | |
| Formaldehyde SCHEMBL27932456 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2D6CYP2C19GRIN2D | |
| SCHEMBL7012924 | 0.81 | ALDH1A1 (0.51) | ALDH1A1CYP1A2CYP2D6CYP2C19GRIN2D | |
| SCHEMBL18225530 | 0.81 | PKM (0.45) | ALDH1A1CYP1A2CYP2D6CYP2C19GRIN2D | |
| SCHEMBL28848348 | 0.81 | ALDH1A1 (0.48) | ALDH1A1CYP1A2CYP2D6CYP2C19CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA UK LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8969350-B2 | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient | ASTRAZENECA AB (SE) | 2015-03-03 | — | — | US | disclosed |
| US-8889692-B2 | Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| EP-2170848-B1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2014-10-22 | — | — | EP | disclosed |
| US-20130012523-A1 | PYRAZINONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | BROUGH STEPHEN (GB) | 2013-01-10 | — | — | US | disclosed |
| US-8299246-B2 | N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses | ASTRAZENECA AB (SE) | 2012-10-30 | — | — | US | disclosed |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | ASTRAZENECA AB (SE) | 2012-08-23 | — | — | US | disclosed |
| US-8163905-B2 | Compounds and their uses 708 | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | ASTRAZENECA UK LIMITED (GB) | 2012-02-02 | — | — | US | disclosed |
| EP-2379174-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| CN-101842361-A | Pyrazinone derivatives and their use in the treatment of lung diseases | ASTRAZENECA AB | 2010-09-22 | — | — | CN | disclosed |
| WO-2010071583-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| EP-2170848-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | AstraZeneca AB (SE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009001132-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| US-4762844-A | ANIMAL GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1988-08-09 | — | — | US | disclosed |
| EP-0181588-A2 | Alkyl-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids, process for their preparation, and antibacterial agents containing them | BAYER AG (DE) | 1986-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | NR3C2, GRK4, PTGER2 | ALDH1A1 1934/4885CYP1A2 690/4885CYP2D6 3003/4885 |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | CYP3A7, CYP2C8, CYP2C18 | ALDH1A1 340/4885CYP1A2 6/4885CYP2D6 4/4885 |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0, CYP3A5 | ALDH1A1 243/4885CYP1A2 12/4885CYP2D6 11/4885 |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | CYP3A7, CYP3A4, CYP2D6 | ALDH1A1 466/4885CYP1A2 9/4885CYP2D6 3/4885 |
| US-20130012523-A1 | PYRAZINONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | CYP3A7, CYP3A5, CYP2C19 | ALDH1A1 484/4885CYP1A2 21/4885CYP2D6 5/4885 |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | NR3C2, ARRB1, GRK4 | ALDH1A1 1798/4885CYP1A2 707/4885CYP2D6 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.